All Work

Trey Thoelcke

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative…

Trey Thoelcke · 5 months ago

5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up

Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each offering a…

Trey Thoelcke · 5 months ago

Apple at 50: What an Investment in the IPO Has Become

Apple (NASDAQ: AAPL | AAPL Price Prediction) went public on December 12, 1980, selling shares at what would become a split-adjusted fraction of a penny. The company that Steve Jobs built around the Apple…

Trey Thoelcke · 5 months ago

Which Chip Equipment Stock Now Offers the Smartest Dip Buy?

Applied Materials (NASDAQ: AMAT | AMAT Price Prediction), ASML (NASDAQ: ASML), KLA (NASDAQ: KLAC), and Lam Research (NASDAQ: LRCX) have all retreated sharply in recent weeks. So which one should a retirement-focused investor buy…

Trey Thoelcke · 5 months ago

Micron’s Future Hinges on 2 Emerging Challenges

Micron Technology (NASDAQ: MU | MU Price Prediction) just posted one of the most impressive quarters in semiconductor history. Earnings surged 771% last quarter, revenue hit $13.64 billion in Q1 FY2026, beating estimates by…

Trey Thoelcke · 5 months ago